BioSpace News Archive

Biotech Bay

Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting

Circle Pharma announced that two poster presentations at the American Association for Cancer Research Annual Meeting held April 14-19, in Orlando, Florida, highlight promising pre-clinical data of its first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors targeting intractable cancers.

April 19, 2023
·
3 min read
Drug Development

Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023

Innovent Biologics, Inc., announced that the overall survival results of the Phase 2 study of pemigatinib in Chinese patients with advanced cholangiocarcinoma were presented at the American Association for Cancer Research Annual Meeting 2023.

April 19, 2023
·
7 min read
Pharm Country

PANTHERx® Rare Announces Release of CUVRIOR™ (trientine tetrahydrochloride) to Treat Wilson Disease

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce the launch of CUVRIOR to treat stable Wilson Disease in adults who are de-coppered and able to take penicillamine.

April 19, 2023
·
4 min read
Policy

InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL

InnoCare Pharma, a leading biopharmaceutical company, announced that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration in the treatment of patients with relapsed/refractory marginal zone lymphoma.

April 19, 2023
·
4 min read